ASKA Pharmaceutical Holdings Co (TSE:4886) Research & Development: 円0 Mil (TTM As of Mar. 2026)


TSE:4886 ASKA Pharmaceutical Holdings Co Ltd TSE:4886
63 GF Score
Price 円2,175.00
GF Value 円2,381.68
Valuation Fairly Valued
View Full Analysis

What is ASKA Pharmaceutical Holdings Co Research & Development?

ASKA Pharmaceutical Holdings Co TSE:4886 -2.77% 63 Research & Development is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:4886 with a GF Score™ of 63/100 and a GF Value™ of 円2,381.68 (Fairly Valued).

Research & Development is the aggregate amount of research and development expenses during the year. ASKA Pharmaceutical Holdings Co's Research & Development for the three months ended in Mar. 2026 was 円0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円0 Mil.

ASKA Pharmaceutical Holdings Co  (TSE:4886) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ASKA Pharmaceutical Holdings Co Research & Development Related Terms

ASKA Pharmaceutical Holdings Co Research & Development Historical Data

* Premium members only.

The historical data trend for ASKA Pharmaceutical Holdings Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ASKA Pharmaceutical Holdings Co Research & Development Chart

ASKA Pharmaceutical Holdings Co Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
0.00 0.00 0.00 0.00 0.00

ASKA Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4886
63GF Score
ASKA Pharmaceutical Holdings Co Ltd TSE:4886
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ASKA Pharmaceutical Holdings Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円0 Mil mean?
ASKA Pharmaceutical Holdings Co (TSE:4886) has a Research & Development of 円0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on ASKA Pharmaceutical Holdings Co and its competitors.
Is ASKA Pharmaceutical Holdings Co's Research & Development too high?
ASKA Pharmaceutical Holdings Co's current Research & Development is 円0 Mil. Overall, ASKA Pharmaceutical Holdings Co has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ASKA Pharmaceutical Holdings Co's Research & Development compare to ZTS?
ASKA Pharmaceutical Holdings Co's Research & Development of 円0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. ASKA Pharmaceutical Holdings Co's current Research & Development is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASKA Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co (TSE:4886) is currently considered Fairly Valued. The stock's GF Value™ is 円2,381.68, compared to a current price of 円2,175.00 — trading 8.7% below its estimated fair value. The current Research & Development is 円0 Mil. ASKA Pharmaceutical Holdings Co's overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ASKA Pharmaceutical Holdings Co (TSE:4886), the current Research & Development is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ASKA Pharmaceutical Holdings Co (TSE:4886) Overvalued in 2026?

Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of 円2,175.00 is trading 8.7% below its estimated GF Value™ of 円2,381.68. GuruFocus considers ASKA Pharmaceutical Holdings Co to be Fairly Valued.

Key valuation signals for TSE:4886:

  • Research & Development: 円0 Mil
  • GF Value™: 円2,381.68 vs. price of 円2,175.00 (8.7% below fair value)
  • GF Score™: 63/100

No single metric tells the full story. See the TSE:4886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ASKA Pharmaceutical Holdings Co Business Description

Address 2-5-1 Shibaura, Minato-ku, Tokyo, JPN, 108-8532
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.
63GF Score

Get the complete analysis for TSE:4886

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,175.00
Price
円2,381.68
GF Value